ARADIGM CORP. ARDM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Marvin Frank who started this subject	9/17/2003 12:33:24 PM
From: Tadsamillionaire	Read Replies (1) of 255

Aradigm Study Shows Promise of Needle-Free System Tuesday September 16, 9:15 am ET HAYWARD, Calif. (Dow Jones)--Aradigm Corp. said results from a study of its Intraject needle-free technology showed that the three best-performing configurations of the product performed acceptably.Based on these results, the company believes at least one of these versions will enable a commercially viable product to be used across a wide variety of drugs. In a press release Tuesday, the maker of drug-delivery systems said the study results will enable it to plan its Intraject development program through the rest of the year. "We will use this information to refine and complete an in vivo/in vitro correlation, and to select and test the final commercial configuration of Intraject," the company said. "This will then allow us to go forward to the final Clinical Performance Verification trial that we anticipate will occur in 2004. Successful completion of this trial will be the trigger for our licensees to commence their bioequivalence studies to demonstrate that Intraject is comparable to the subcutaneous injection delivery of their compounds." biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next